REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Telomere Defense Stack

Anti-Aging & Longevityintermediate
33
Share
Peptides

3

Avg Daily mcg

7,443

Level

intermediate

Added

May 16, 2026

Overview

The Telomere Defense Stack is an intermediate-level longevity protocol designed to protect and restore chromosomal integrity while optimizing mitochondrial function. This stack addresses two of the most fundamental hallmarks of aging: telomere attrition and mitochondrial dysfunction, making it one of the most scientifically grounded anti-aging peptide combinations available. Epithalon, administered at 5000mcg daily, is the centerpiece of this protocol and the only known peptide demonstrated to activate telomerase in human somatic cells. Developed from decades of research by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon is a synthetic tetrapeptide that mimics the natural pineal gland peptide Epithalamin. Clinical research has shown it can increase telomere length, normalize circadian rhythm function, and restore melatonin production to youthful levels. By maintaining telomere length, Epithalon helps prevent cells from entering senescence, the state where damaged cells accumulate and drive systemic inflammation and tissue deterioration. MOTS-c, dosed at 5000mcg three times per week, is a mitochondrial-derived peptide that acts as a powerful metabolic regulator. It activates AMPK signaling pathways, improves insulin sensitivity, and enhances cellular energy production. Research has shown MOTS-c can reprogram cellular metabolism to resist age-related decline, improve exercise capacity, and reduce accumulation of metabolic waste products. It works synergistically with Epithalon by ensuring that cells with preserved telomere length also maintain robust energy production capabilities. GHK-Cu at 300mcg daily adds broad-spectrum anti-aging gene modulation to the stack. Studies have identified over 4,000 genes whose expression is positively influenced by GHK-Cu, many of which are involved in DNA repair, antioxidant defense, and stem cell maintenance. This creates a supportive environment for the telomere-protective and mitochondrial effects of the other peptides. This stack is ideal for health-conscious individuals over 35 seeking to address aging at its root causes rather than its symptoms. Run in 20-day cycles with 10-day breaks for Epithalon, while MOTS-c and GHK-Cu can continue uninterrupted. Morning administration is preferred, and periodic telomere length testing can help track progress over multiple cycles.

Dosing Protocol

5,000 mcg

per dose

MOTS-c

3 times per week

Read more about MOTS-c →

5,000 mcg

per dose

300 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.